2016年是中国肿瘤防治重要的一年。回顾了中国2016年在肿瘤预防领域采取的环境治理、防治肥胖、大病医保及健康体检等措施，简述了在治疗肺癌、白血病、乳腺癌、消化道癌和鼻咽癌等方面取得的重要进展，盘点了新药研发、免疫治疗和转化医学研究平台建设等方面取得的成绩，分析了中国肿瘤防治的发展前景。
2016 was an important year for cancer control in China. This report presents the progress and achievements in cancer prevention including environment management,smoking control, obesity prevention, health insurance of serious illness, annual check-up; the major achievements in the treatment of lung cancer, leukemia, breast cancer, gistrointestinal cancer and nasopharrengeal cancer; as well as developments of new anticancer agents, immune treatment and construction of translational research platforms. The perspective of cancer prevention and treatment in the near future is also briefly discussed.
[1] (NCD-RisC) NRFC. Trends in adult body-mass index in 200 countries from 1975 to 2014:A pooled analysis of 1698 population-based measurement studies with 19.2 million participants[J]. Lancet, 2016, 387(10026):1377-1396.
[2] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[3] Shi Y, Wang L, Han B, et al. First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE)[J]. J Clin Oncol, 2016, 34(Suppl):Abstr 9041.
[4] Cheng Y. Randomized phase ii trial of gifitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth receptor mutations[J]. J Clin Oncol, 2016, 34(27):3258-3266.
[5] Wu Y. BRAIN:A phase-trial comparing wbi and chemotherapy with icotinib in NSCLC with Brain metastases harboring EGFR mutations[C]//17th World Conference on Lung Cancer (WCLC). 2016:Abstract PL03.05.
[6] Dai C. Choice of surgical procedure for patients with non-small-cell lung cancer≤1 cm or >1 to 2 cm among lobectomy, segmentectomy, and wedge resection:A population-based study[J]. J Clin Oncol, 2016, 34(26):3175-82.
[7] Harbeck N, Huang C S, Hurvitz S, et al. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1):An open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2016, 17(3):357-366.
[8] Xu B, Sun T, Zhang Q, et al. Randomized phase III trial of utidelone, a genetically engineered epothilone analog, in combination with capecitabine versus capecitabine alone for metastatic breast cancer patients with previous taxane and anthracycline treatment[C]//2016 American Society of Clinical Oncology (ASCO). 2016:Abstract 1004.
[9] Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase iii trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. J Clin Oncol, 2016, 34(13):1448-1450.
[10] Qin S, Xu J, Wang L, et al. LBA-05:First-line FOLFOX-4±cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC):The open-label, randomized phase 3 TAILOR trial[J]. Annals of Oncology, 2016, 27(Suppl 2):ii141.
[11] Zhang L. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma:a multicentre, randomised, open-label, phase 3 trial[J]. Lancet, 2016, 388(10054):1883-1892.
[12] Yihebali C, Sun Y, J, Cai J, et al. Phase II study of anlotinib for treatment of advanced softtissues sarcomas[C]//2016 American Society of Clinical Oncology(ASCO). 2016:Abstract 11005.
[13] Mok T S. Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung cancer[J]. N Engl J Med, 2016-12-06[Epub ahead of print].
